239 related articles for article (PubMed ID: 32085733)
41. Carbonic anhydrase 1 is a promising biomarker for early detection of non-small cell lung cancer.
Wang DB; Lu XK; Zhang X; Li ZG; Li CX
Tumour Biol; 2016 Jan; 37(1):553-9. PubMed ID: 26232327
[TBL] [Abstract][Full Text] [Related]
42. Diagnostic significance of S100A2 and S100A6 levels in sera of patients with non-small cell lung cancer.
Wang T; Liang Y; Thakur A; Zhang S; Yang T; Chen T; Gao L; Chen M; Ren H
Tumour Biol; 2016 Feb; 37(2):2299-304. PubMed ID: 26361956
[TBL] [Abstract][Full Text] [Related]
43. Differential miRNA expressions in peripheral blood mononuclear cells for diagnosis of lung cancer.
Ma J; Lin Y; Zhan M; Mann DL; Stass SA; Jiang F
Lab Invest; 2015 Oct; 95(10):1197-206. PubMed ID: 26146958
[TBL] [Abstract][Full Text] [Related]
44. Serum pleiotrophin could be an early indicator for diagnosis and prognosis of non-small cell lung cancer.
Du ZY; Shi MH; Ji CH; Yu Y
Asian Pac J Cancer Prev; 2015; 16(4):1421-5. PubMed ID: 25743809
[TBL] [Abstract][Full Text] [Related]
45. Cortisol, cortisone, and 4-methoxyphenylacetic acid as potential plasma biomarkers for early detection of non-small cell lung cancer.
Xiang C; Jin S; Zhang J; Chen M; Xia Y; Shu Y; Guo R
Int J Biol Markers; 2018 Aug; 33(3):314-320. PubMed ID: 29896992
[TBL] [Abstract][Full Text] [Related]
46. Plasma
Wang K; Song X; Li X; Zhang Z; Xie L; Song X
Future Oncol; 2022 Mar; 18(7):821-832. PubMed ID: 34842456
[No Abstract] [Full Text] [Related]
47. Serum miR-152, miR-148a, miR-148b, and miR-21 as novel biomarkers in non-small cell lung cancer screening.
Yang JS; Li BJ; Lu HW; Chen Y; Lu C; Zhu RX; Liu SH; Yi QT; Li J; Song CH
Tumour Biol; 2015 Apr; 36(4):3035-42. PubMed ID: 25501703
[TBL] [Abstract][Full Text] [Related]
48. [OLC1 protein levels in plasma of patients with non-small cell lung cancer and its clinical application].
Yang L; Xiao T; Tan J; Chen S; Gao Y; Cheng S; Liu X; Sun K
Zhonghua Zhong Liu Za Zhi; 2014 May; 36(5):362-5. PubMed ID: 25030592
[TBL] [Abstract][Full Text] [Related]
49. Development of a Protein Biomarker Panel to Detect Non-Small-Cell Lung Cancer in Korea.
Jung YJ; Katilius E; Ostroff RM; Kim Y; Seok M; Lee S; Jang S; Kim WS; Choi CM
Clin Lung Cancer; 2017 Mar; 18(2):e99-e107. PubMed ID: 27836219
[TBL] [Abstract][Full Text] [Related]
50. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer.
Lam S; Boyle P; Healey GF; Maddison P; Peek L; Murray A; Chapman CJ; Allen J; Wood WC; Sewell HF; Robertson JF
Cancer Prev Res (Phila); 2011 Jul; 4(7):1126-34. PubMed ID: 21733826
[TBL] [Abstract][Full Text] [Related]
51. Combined identification of long non-coding RNA XIST and HIF1A-AS1 in serum as an effective screening for non-small cell lung cancer.
Tantai J; Hu D; Yang Y; Geng J
Int J Clin Exp Pathol; 2015; 8(7):7887-95. PubMed ID: 26339353
[TBL] [Abstract][Full Text] [Related]
52. Multiplex plasma protein profiling identifies novel markers to discriminate patients with adenocarcinoma of the lung.
Djureinovic D; Pontén V; Landelius P; Al Sayegh S; Kappert K; Kamali-Moghaddam M; Micke P; Ståhle E
BMC Cancer; 2019 Jul; 19(1):741. PubMed ID: 31357969
[TBL] [Abstract][Full Text] [Related]
53. Plasma biomarkers distinguish non-small cell lung cancer from asthma and differ in men and women.
Izbicka E; Streeper RT; Michalek JE; Louden CL; Diaz A; Campos DR
Cancer Genomics Proteomics; 2012 Jan; 9(1):27-35. PubMed ID: 22210046
[TBL] [Abstract][Full Text] [Related]
54. Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease.
Szpechcinski A; Chorostowska-Wynimko J; Struniawski R; Kupis W; Rudzinski P; Langfort R; Puscinska E; Bielen P; Sliwinski P; Orlowski T
Br J Cancer; 2015 Jul; 113(3):476-83. PubMed ID: 26125447
[TBL] [Abstract][Full Text] [Related]
55. Clinical significance of serum miR-25 in non-small-cell lung cancer.
Li J; Yu M; Liu Z; Liu B
Br J Biomed Sci; 2019 Jul; 76(3):111-116. PubMed ID: 30919763
[No Abstract] [Full Text] [Related]
56. [Macrophage Inhibitory Cytokine-1 (MIC-1) as A Biomarker for Diagnosis
and Prognosis of Stage I-II Non-small Cell Lung Cancer].
Liu Y; Wang X; Wang T; Zhang C; Zhang K; Zang R; Zhi X; Zhang W; Sun K
Zhongguo Fei Ai Za Zhi; 2016 Apr; 19(4):207-15. PubMed ID: 27118648
[TBL] [Abstract][Full Text] [Related]
57. Machine Learning for Early Lung Cancer Identification Using Routine Clinical and Laboratory Data.
Gould MK; Huang BZ; Tammemagi MC; Kinar Y; Shiff R
Am J Respir Crit Care Med; 2021 Aug; 204(4):445-453. PubMed ID: 33823116
[No Abstract] [Full Text] [Related]
58. Relevance of matrix metalloproteases in non-small cell lung cancer diagnosis.
Blanco-Prieto S; Barcia-Castro L; Páez de la Cadena M; Rodríguez-Berrocal FJ; Vázquez-Iglesias L; Botana-Rial MI; Fernández-Villar A; De Chiara L
BMC Cancer; 2017 Dec; 17(1):823. PubMed ID: 29207990
[TBL] [Abstract][Full Text] [Related]
59. Seven tumor-associated autoantibodies as a serum biomarker for primary screening of early-stage non-small cell lung cancer.
Chen P; Lu W; Chen T
J Clin Lab Anal; 2021 Nov; 35(11):e24020. PubMed ID: 34555232
[TBL] [Abstract][Full Text] [Related]
60. Diagnostic and Prognostic Value of Serum Angiopoietin-Like Protein 2 in Patients with Non-Small Cell Lung Cancer.
Chen Y; Jiang H; Zhu L; Wang P; Liu S; Xiao X; Yu H; Dong W
Clin Lab; 2017 Jan; 63(1):59-65. PubMed ID: 28164488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
